Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid prophylaxis against glucocorticoid-induced osteoporosis in lymphoma
2026-527220-27-00Phase 3Authorised
- Sponsor
- Region Nordjylland
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of zoledronic acid in glucocorticoid-induced osteoporosis (GIOP), sponsored by Region Nordjylland. Primary endpoint: Fracture rate at 2 years in completer group. Planned start Sep 2026; status: authorised.
02
Drugs
zoledronic acid
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on 2026-527220-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527220-27-00.